It is currently Fri Dec 19, 2014 1:33 am

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

IMMUNE TRETMENT FOR MS SHOWS PROMISE

HI Friends please read for details
http://www.medicalnewstoday.com/articles/272326.php
regards
seeva
Read more : IMMUNE TRETMENT FOR MS SHOWS PROMISE | Views : 175 | Replies : 0


MS DRUG DOESN'T PREVENT ONSET OF DISABILITY, STUDY FOUND

FRIENDS Most widely prescribed drug for treating ms has little or no efect of patients progression to disability, a new study has found please read more
http://www.nytimes.com/2012/07/18/healt ... hare&_r=1&
regards
seeva
Read more : MS DRUG DOESN'T PREVENT ONSET OF DISABILITY, STUDY FOUND | Views : 495 | Replies : 3




NEW VACCINE TESTED AGAINST AUTOIMMUNE DISEASES

http://nocamels.com/2012/01/new-vaccine ... -diseases/
ISRAELI scientists from Weizmann Institute of silence think they have made progress what could be significant progress in the treatment of autoimmune diseases
read more from the attached
regards
seeva
Read more : NEW VACCINE TESTED AGAINST AUTOIMMUNE DISEASES | Views : 392 | Replies : 1


VACCINE AGAINST MS BEING DEVELOPED AT BAYLOR INSTITUTE FOR I

Vaccine Against MS Being Developed at Baylor Institute for Immunology Research
FRIENDS PL READ
SEEVA
Read more : VACCINE AGAINST MS BEING DEVELOPED AT BAYLOR INSTITUTE FOR I | Views : 322 | Replies : 1


IVIG

Lyme disease triggered my MS about 25 yrs ago. There was a time when I took ivig50 g per month and it was helping. Thus January cigna denied coverage. Had to go to HR, got it covered again. Getting port on Tuesday.
I have tried Copaxone, calcium EAP, Prokarin, B1/liver extract shots but I am hoping the ivig will help me get to a better place.

Just sharing my experience w IVIG
Read more : IVIG | Views : 197 | Replies : 0


Secondary progressive MS therapy MIS416 dosing trial....

Secondary progressive MS therapy MIS416 dosing trial underway

New Zealand and Australia-based Innate Immunotherapeutics Limited, a medical biotechnology company with offices in Sydney and Auckland, has issued an update regarding its Phase 2B trial for secondary progressive multiple sclerosis (SPMS) and other recent activities.

The Phase 2B MIS416 trial Patient dosing with MIS416 is now underway at the West Australian Neuroscience Institute (WANRI) in Perth and at Nucleus Network’s AMREP Centre for Clinical Studies in ...
Read more : Secondary progressive MS therapy MIS416 dosing trial.... | Views : 222 | Replies : 0


Anemone toxin inhibits KV1.3

The Alliance for Children's Therapeutics in collaboration with Dr. Anne Stevens of Seattle Children's Hospital and Kineta Biotech are developing a synthetic protein known as Shk-186. Based on a toxin from the Sun Anemone, Shk-186 inhibits the potassium channel KV1.3 in effector memory T cells and blocks the proinflammatory cytokine cascade leading to autoimmunity.

http://www.childrenstherapeutics.org/treatments.html

http://www.kinetabio.com/autoimmune.html

http://www.seattlechildrens.org/researc ... evens-lab/ ...
Read more : Anemone toxin inhibits KV1.3 | Views : 189 | Replies : 0


Synthetic protein targets EBV

UW researchers at the Institute of Protein Design have developed a synthetic protein called BINDI which binds to the Epstein-Barr Virus (EBV) protein BHRF1 responsible for immortalizing cells. Inhibition of BHRF1, a BCL2 homologue, may prove to be a useful treatment for EBV related cancers and other conditions stemming from EBV.

http://www.ipd.uw.edu/designer-proteins ... cer-cells/

http://www.cell.com/cell/abstract/S0092 ... %2900613-8
Read more : Synthetic protein targets EBV | Views : 158 | Replies : 0


Drug effectiveness in doubt.

On March 21, 2013 it was announced that Professor George C. Ebers, MD, of University of Oxford in London, had been chosen to receive the National MS Society/American Academy of Neurology’s 2013 John Dystel Prize for Multiple Sclerosis. The following quotes come from http://www.nationalmssociety.org site.

QUOTE
"His studies of twins have shown that susceptibility is partly genetic and partly environmental, indicating that MS is a complex genetic disease. These ...
Read more : Drug effectiveness in doubt. | Views : 358 | Replies : 0


 

Login  •  Register


Statistics

Total posts 222241 • Total topics 23082 • Total members 14609


Contact us | Terms of Service